Q-Sera announces first product launch of its RAPClot™
Uniseed-backed Australian medtech Q-Sera's blood-clotting tube technology has debuted in Japan via Terumo's VenoJect II launch; the post also credits MRCF and UniQuest Extension Fund as backers.
Company
Manufacturer of Q-Sera’s recombinant ecarin
Every investor coverage indicates participated in a round Bora Biologics raised.
Companies Bora Biologics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Bora Biologics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Uniseed-backed Australian medtech Q-Sera's blood-clotting tube technology has debuted in Japan via Terumo's VenoJect II launch; the post also credits MRCF and UniQuest Extension Fund as backers.
Q-Sera's rapid-clotting blood tube technology has gone to market in Japan via Terumo's VenoJect II launch; the Melbourne startup's backers include MRCF, Uniseed and the UniQuest Extension Fund.